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Abstract
 Background—Patients with end-stage renal disease (ESRD) receiving dialysis have been 
reported to have increased risk of cancer. However, contemporary cancer burden estimates in this 
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population are sparse and do not account for the high competing risk of death characteristic of 
dialysis patients.
 Study Design—Retrospective cohort study.
 Setting & Participants—US adult patients enrolled in Medicare's ESRD program who 
received in-center hemodialysis.
 Factors—Demographic/clinical characteristics.
 Outcomes—For overall and site-specific cancers identified using claims-based definitions, we 
calculated annual incidence rates (1996-2009). We estimated 5-year cumulative incidence since 
dialysis therapy initiation using competing-risk methods.
 Results—We observed a constant rate of incident cancers for all sites combined, from 3,923 to 
3,860 cases per 100,000 person-years (annual percentage change, 0.1; 95% CI, −0.4 to 0.6). Rates 
for some common site-specific cancers increased (ie, kidney/renal pelvis) and decreased (ie, colon/
rectum, lung/bronchus, pancreas, and other sites). Of 482,510 incident hemodialysis patients, 
cancer was diagnosed in 37,128 within 5 years after dialysis therapy initiation. The 5-year 
cumulative incidence of any cancer was 9.48% (95% CI, 9.39%-9.57%) and was higher for certain 
subgroups: older age, males, nonwhites, non-Hispanics, nondiabetes primary ESRD cause, recent 
dialysis therapy initiation, and history of transplantation evaluation. Among blacks and whites, we 
observed 35,767 cases compared with 25,194 expected cases if the study population had 
experienced rates observed in the US general population (standardized incidence ratio [SIR], 1.42; 
95% CI, 1.41-1.43). Risk was most elevated for cancers of the kidney/renal pelvis (SIR, 4.03; 95% 
CI, 3.88-4.19) and bladder (SIR, 1.57; 95% CI, 1.51-1.64).
 Limitations—Claims-based cancer definitions have not been validated in the ESRD 
population. Information for cancer risk factors was not available in our data source.
 Conclusions—These results suggest a high burden of cancer in the dialysis population 
compared to the US general population, with varying patterns of cancer incidence in subgroups.
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Despite reports of increased risk of various cancers in the dialysis population,- the 
contemporary cancer burden has not been characterized adequately among patients with 
end-stage renal disease (ESRD) receiving dialysis. In the past 3 decades, several national 
population-based analyses that identified cancer cases using statutory notifications or billing 
codes have yielded estimates of cancer incidence in the ESRD population.,,- However, 
population-based estimates of cumulative incidence or annual incidence rates are not 
available. Furthermore, information is sparse for cancer incidence in dialysis patients by 
subgroups such as age, sex, race, ethnicity, primary cause of ESRD, and dialysis vintage. 
Current estimates of cancer incidence in the ESRD population are important to inform 
cancer-related health care policy and planning for the US Medicare program.
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The objective of this study was to describe the cancer burden among ESRD patients 
receiving hemodialysis, including relevant patient subgroups. Using data from the US Renal 
Data System (USRDS), a national registry including all patients in Medicare's ESRD 
program, we described temporal trends in cancer incidence rates (1996-2009). In addition, 
we estimated the cumulative incidence and relative risk of all cancers combined, as well as 
site-specific cancers, since dialysis therapy initiation. We used competing-risk methods to 
avoid inflating the estimated risk of cancer by censoring the deaths that occurred prior to 
cancer diagnosis (ie, the event of interest).-
 METHODS
 Data and Population
We used data from the USRDS, a national registry that includes all patients in Medicare's 
ESRD program. The study population included patients with ESRD 18 years or older who 
received in-center hemodialysis within the period from April 1, 1995, through December 31, 
2010. The study population was restricted to individuals with Medicare as their primary 
payer and both Parts A and B coverage in order to ensure collection of complete claims data 
for patients. Patients were excluded for a history of HIV (human immunodeficiency virus) 
infection/AIDS or a malignancy-related primary cause of ESRD.
The study population was limited to patients who remained alive without a cancer diagnosis 
for at least 9 months after dialysis therapy initiation. This period was selected because 3 
months after the first service date is the time required to process Medicare eligibility/
enrollment forms and to ensure stability in dialysis treatment modality. A subsequent 6-
month period (ie, the baseline period) was required for assessment of cancer-free status, as 
done previously.- History of kidney transplantation evaluation was defined as a claim 
assigned a V code of V72.83 (other specified preoperative examination) during the 6-month 
baseline period. Sensitivity and specificity of code V72.83 have not been reported.
 Outcomes
We identified incident site-specific cancers using International Classification of Diseases, 
Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes from inpatient and 
outpatient Medicare claims. Table S1 (provided as online supplementary material) presents 
the ICD-9-CM codes used in the site-specific cancer definitions. The claims-based algorithm 
used to define site-specific cancers required 2 or more ICD-9-CM diagnosis codes within 6 
months, adapted from an algorithm (requiring ≥2 ICD-9-CM diagnosis codes within 2 
months) validated in a Medicare population for identification of incident cancers, including 
lung, colorectal, stomach, breast, and lymphoma (sensitivity: range, 56%-77%; specificity: 
≥99%; positive predictive value: range, 56%-77%). We extended the period to 6 months 
between cancer diagnosis codes to allow for delays in health care encounters that may occur 
due to the high severity of illness characteristic of the ESRD population. Date of cancer 
onset was defined as the first date of a cancer-related diagnosis code in the claims data. In 
situ carcinomas were included for 2 sites (ie, breast and bladder), in accordance with the 
Surveillance, Epidemiology, and End Results (SEER) Program. Secondary tumors, benign 
tumors, and nonmelanoma skin cancers were excluded from the analysis. Only the first 
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cancer diagnosis after dialysis therapy initiation was included as an event. Patients with 
multiple cancer sites diagnosed on the same date were included in each site-specific 
analysis.
 Annual Incidence Rates of Cancer
We used 14 annual cohorts (ie, 1996-2009) of prevalent hemodialysis patients who met 
eligibility criteria by January 1 to calculate incidence rates of cancer. All patients with 
ESRD who initiated in-center hemodialysis on or before April 1 of the previous year and 
remained alive on January 1 of the cohort year were eligible for that yearly cohort. Patients 
were eligible for multiple cohorts. Patients with cancer during the 6-month baseline period 
(ie, July 4 to December 31 of the prior year) were excluded from that yearly cohort. Patients 
were observed from 9 months post–dialysis therapy initiation to the first cancer diagnosis. 
Patients were censored due to loss of Medicare as primary payer status, change of modality, 
loss to follow-up, kidney transplantation, death, or end of study (December 31 of the cohort 
year).
Annual incidence rates, expressed as cancer diagnoses per 100,000 patients per year, were 
calculated overall and within strata of patient characteristics. To derive cancer rates adjusted 
for secular trends, we computed a standardized mortality ratio–weighted model using the 
2000 population as the standard, as previously described. Incidence rates were adjusted for 
age at dialysis therapy initiation, sex, race, ethnicity, primary cause of ESRD, and dialysis 
vintage in years. The Joinpoint Regression Program (version 4.0.4; National Cancer 
Institute) was used to model trends of adjusted annual incidence rates during the study 
period (1996-2009) and calculate annual percentage change and 95% confidence intervals 
(CIs)., Further details are described in Item S1.
 Cumulative Incidence Estimates of Cancer
We used a retrospective cohort of incident patients who initiated in-center hemodialysis 
between April 1, 1995, and April 5, 2010, to estimate the cumulative incidence of cancer. 
The retrospective cohort design spanned the 5 years after dialysis therapy initiation, 
including a 3-month eligibility period, a subsequent 6-month baseline period, and a follow-
up period for up to 5 years after dialysis therapy initiation. Time at risk was measured from 
9 months after dialysis therapy initiation to the first of the following: the event of interest (ie, 
cancer diagnosis) or censoring (ie, cancer diagnosis at another site, renal replacement 
therapy modality change to peritoneal dialysis or kidney transplantation, end of Medicare as 
primary payer status, loss to follow-up, 5 years since dialysis therapy initiation, or end of 
study on December 31, 2010).
We estimated the cumulative incidence of cancer accounting for the competing risk of death. 
Cumulative incidence is defined as the probability of cancer given that an individual has 
survived up to time t without cancer or has had a competing event of death prior to time t. 
The competing-risks model specifies that individuals who experience the competing event 
remain in the risk set for the event of interest. Thus, the risk set includes 2 distinct groups: 
those who have not failed from any cause and those who have previously failed from a 
competing event., This analysis required a customized SAS program (SAS Institute Inc).
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Item S1 also presents the cumulative incidence analysis ignoring the competing risk of death 
(ie, censoring death).
In the analysis accounting for the competing risk of death, crude and standardized 
cumulative incidence estimates were stratified by several patient characteristics. We used 
inverse probability of exposure weights to standardize each stratum to the total study sample 
at baseline with respect to age, sex, race, ethnicity, primary cause of ESRD, and calendar 
year of dialysis therapy initiation, as appropriate. Inverse probability exposure weights were 
calculated as the marginal proportion of patients receiving the level of exposure they 
received (ie, the stabilizing factor) divided by the predicted probability of receiving that 
exposure from the linear logistic model. For each patient characteristic, we fit both a null 
linear logistic model to calculate the marginal proportion of exposure and a full linear 
logistic model to calculate the predicted probability of a particular exposure level for each 
combination of covariates. Age was modeled using restricted quadratic splines, with 4 knots 
placed at the 5th, 35th, 65th, and 95th percentiles of the age distribution in the study sample.
Table S2 presents descriptive characteristics of the inverse probability exposure weights. We 
also estimated the inverse probability of censoring weights to account for informative 
censoring (Item S1). We obtained 95% CIs as a measure of uncertainty due to sampling error 
using a nonparametric bootstrap. Specifically, we resampled 482,510 patients at random 
with replacement with equal probability 200 times. The standard deviation of the 200 
bootstrap resamples was used as an estimate of the standard error.
 Standardized Incidence Ratios
To estimate the risk of cancer in the study population of incident hemodialysis patients 
relative to that of the US general population, we calculated the standardized incidence ratio 
(SIR) by dividing the number of observed cancer cases by the number of expected cancer 
cases from 1996 through 2009. We calculated 95% CIs under the assumption that the 
number of observed cancer cases followed a Poisson distribution. To estimate the number of 
expected cancer cases, we multiplied the age-, sex-, and race-specific incidence rates from 
the US general population (SEER 13 registry data via SEER*Stat, version 8.1.5) by the 
number of person-years at risk for each age, sex, and race stratum in the study population. 
Analysis was limited to whites and blacks due to limited availability of rate estimates for 
other race in the SEER general population. SAS software, version 9.3 (SAS Institute Inc), 
was used for all analyses.
 RESULTS
 Annual Incidence Rates of Cancer
Table 1 lists characteristics of the study population of prevalent dialysis patients for selected 
years of the study period. The number of patients per annual cohort increased each year, 
from 88,676 in 1996 to 164,214 in 2009. Patients were more likely to be male, be white, or 
have diabetes as the primary cause of ESRD in recent cohorts. Mean age and mean dialysis 
vintage increased during the study period.
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Adjusted annual incidence rates of cancer are presented in Fig 1. We observed a constant 
rate of incident cancer diagnoses for all sites for 1996 to 2009, from 3,923 to 3,860 cases per 
100,000 person-years (annual percentage change, 0.1%; 95% CI, −0.4% to 0.6%; Table 2). 
From 1996 through 2009, incidence rates increased for cancers of the kidney/renal pelvis; 
decreased for cancers of the colon/rectum, lung/bronchus, pancreas, and other sites 
(1996-2003 only); and remained constant for cancers of the prostate, female breast, bladder, 
non-Hodgkin lymphoma, and other sites (2003-2009 only; Table 2). Across all calendar 
years, cancers of the prostate and female breast were the most commonly diagnosed, 
representing 1,195 and 718 cases per 100,000 person-years in 2009, respectively.
Figure 2 presents adjusted incidence rates for the 4 most frequently diagnosed cancer sites 
stratified by subgroups. Adjusted incidence rates were much higher among older patients 
and males and less common among patients with diabetes as the primary cause of ESRD. 
Prostate cancer had the highest incidence rate across all except 4 strata (ie, age < 65 years, 
female, nonwhite, or diabetes as primary cause of ESRD).
 Cumulative Incidence Estimates of Cancer
Of 482,510 patients who met study eligibility requirements (Fig S1; Table S3), 48.4% were 
female, 62.7% were white, 32.0% were African American, and 13.1% were Hispanic. The 
most common reported causes of ESRD were diabetes (50.4%) and hypertension (30.5%). 
Median age at dialysis therapy initiation was 67 years (Table S4). Median follow-up after 
dialysis therapy initiation was 2.5 years.
During 988,395 person-years of follow-up between 9 months and 5 years after dialysis 
therapy initiation, 37,128 patients were given a diagnosis of cancer (including 667 patients 
with multiple cancer sites diagnosed on the same date). A total of 217,773 (45.1%) patients 
died prior to receipt of a cancer diagnosis. Twelve percent (n = 57,345) of the 482,510 
patients were censored alive and cancer free before 5 years of follow-up or December 31, 
2010.
The 5-year crude cumulative incidence of any cancer accounting for death as a competing 
risk was 9.48% (95% CI, 9.39%-9.57%; Fig 3). Table 3 presents crude and standardized 5-
year cumulative incidence estimates of any cancer accounting for death as a competing risk, 
stratified by patient characteristics. Figs 4 and S2 present standardized and crude cumulative 
incidence estimates accounting for death as a competing risk, by time from dialysis therapy 
initiation. Results were not altered meaningfully when drop out was not accounted for in the 
analysis (~1% change; results not shown). After accounting for case-mix characteristics 
measured at baseline and the competing risk of death, the 5-year cumulative incidence of 
any cancer was higher among the following patient subgroups: persons 65 years or older at 
dialysis therapy initiation (11.28%), males (10.93%), nonwhites (9.79%), non-Hispanics 
(9.65%), primary ESRD cause other than diabetes (hypertension, 10.39%; other, 11.54%; 
glomerulonephritis, 12.01%), dialysis therapy initiation in 2003 to 2010 (9.75%), and 
history of kidney transplantation evaluation (11.67%). Figure S3 presents crude cumulative 
incidence estimates that censored deaths, stratified by patient characteristics.
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Tables 4 and S4 present results from more and less common site-specific cancer analyses (ie, 
≥150 and <150 site-specific cancer cases during the study period). The most frequently 
diagnosed cancer sites were prostate (n = 5,396), lung/bronchus (n = 4,969), colon/rectum (n 
= 4,360), female breast (n = 3,688), kidney/renal pelvis (n = 2,805), bladder (n = 2,216), 
non-Hodgkin lymphoma (n = 1,284), leukemia (n = 1,077), myeloma (n = 1,024), and 
pancreas (n = 928). Results from the cumulative incidence analysis treating death as a 
censoring event are available in Table S5.
 Standardized Incidence Ratios
From 1996 through 2009, a total of 35,767 cancer cases were observed in the study 
population of black and white dialysis patients compared with 25,194 expected cases if the 
study population had experienced the rates observed in the US general population (SIR, 
1.42; 95% CI, 1.41-1.43). Relative risk was elevated for all 8 of the most common incident 
site-specific cancers diagnosed in the study population. Risk was most elevated for cancers 
of the kidney/renal pelvis (SIR, 4.03; 95% CI, 3.88-4.19) and bladder (SIR, 1.57; 95% CI, 
1.51-1.64; Table 5).
 DISCUSSION
We conducted a large national study of patients with ESRD undergoing hemodialysis to 
describe the incidence of cancer in this population. After accounting for the substantial 
competing risk of death in the ESRD population undergoing dialysis, we observed a high 
cumulative incidence of cancer, with >9% of the ESRD population being diagnosed with 
cancer during a 5-year period after initiating dialysis therapy. From 1996 through 2009, we 
observed constant rates of incident cancer diagnoses for all sites combined. For certain site-
specific cancers, there were trends of increasing and decreasing incidence rates. In addition, 
our results demonstrate varying patterns of cancer incidence in subgroups after accounting 
for measured patient characteristics. To our knowledge, there are no previous population-
based estimates of cumulative incidence or annual incidence rates of cancer in the dialysis 
population. Therefore these estimates provide novel information on the cancer burden in this 
unique population.
The 5-year cumulative incidence estimate of 9.48% depends on the risk of both cancer and 
the competing event of death that precludes development of cancer. The competing-risk 
approach provides an estimate of the total amount of cancer diagnoses that will occur in the 
population, which may provide estimates with greater accuracy and precision for health care 
policy and planning in the dialysis population characterized by very high mortality. Despite 
the higher cancer risk previously documented among transplant recipients compared with 
dialysis patients, our 5-year cumulative incidence estimate is much higher than the 4.4% 
estimate among US transplant recipients reported by Hall et al., This discrepancy can be 
explained largely by the substantially younger age of the transplantation population 
compared to our dialysis population (ie, aged ≤60 years: 84% vs 32%) and is supported by 
the steep increase in cumulative incidence of cancer with increasing age at transplantation.
We observed an increased risk of cancer in the dialysis population compared to the risk 
expected if the study population had experienced the rates observed in the US general 
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population. These results suggest that patients with ESRD are uniquely at risk for 
developing cancer while receiving hemodialysis treatment. Our estimates are similar yet 
slightly higher than most estimates from previous population-based studies of cancer in the 
dialysis population, which have reported increased risk for any cancer (SIR range, 1.1-1.8) 
compared to the general population.,, One exception is a recent SEER-Medicare study 
restricted to patients older than 65 years, which reported no increased overall risk of cancer 
in patients with ESRD compared to the general population. However, this discrepancy may 
be due to inadvertent inclusion of non-ESRD patients with less severe kidney disease, with 
reportedly lower risk of cancer than patients with ESRD receiving dialysis.
For some cancer sites (ie, prostate, female breast, lung/bronchus, colon/rectum, and non-
Hodgkin lymphoma), our analyses yielded slightly higher cancer burden estimates than most 
previous population-based studies of cancer in the dialysis population.,,, The most notable 
result is the excess risk for prostate cancer (SIR, 1.06; 95% CI, 1.03-1.09), which contrasts 
with most previous reports of diminished risk (SIR range, 0.4-1.2).,,, There are several 
explanations for the higher cancer burden estimates yielded by our analyses. First, our 
cancer definition captured cancer diagnoses occurring in the outpatient setting, whereas the 
cancer definition used in a previous study with the same USRDS population captured only 
cancer-related hospitalizations. Several cancer sites, including prostate, are increasingly 
screened, diagnosed, and treated exclusively in the outpatient setting. Thus, requiring 
hospital admission could underestimate the true cancer burden in the dialysis population. 
Second, our higher cancer estimates could be due to improved survival in the dialysis 
population. In our analysis that censored deaths, we observed that 5-year cumulative 
incidence was similar by era of dialysis therapy initiation. In contrast, the competing-risks 
approach (which allowed patients who died to remain in the denominator of patients at risk) 
yielded a higher 5-year cumulative incidence estimate among patients who initiated dialysis 
therapy in 2003 to 2010 versus 1995 to 2002. This suggests that the higher cancer incidence 
in the most recent era is due to improved survival in the dialysis population. Thus, 
differences in mortality by era could contribute to lower cancer burden estimates in older 
studies.
We observed a similar pattern in the comparison between patients with and without a kidney 
transplantation evaluation, in which patients with an evaluation had a higher cancer 
incidence due to longer survival. Another explanation for a higher 5-year cumulative 
incidence of cancer among patients who received a kidney transplantation evaluation, 
despite a healthier profile than patients who did not receive an evaluation, is unexpected 
cancer diagnoses yielded by intensive medical workup involving comprehensive cancer 
screening. Our finding should be interpreted with caution due to the unknown validity and 
reliability of the code used to define kidney transplantation evaluation.
Several explanations for increased cancer incidence in the dialysis population have been 
suggested, including ESRD-associated immunodeficiency and nutritional abnormalities.-
Excess cancer risk also may be due to the interaction of uremic and dialysis-induced 
immune dysfunction with established risk factors (eg, UV radiation, tobacco, or alcohol).
Recently, there has been a focus on the potential role of erythropoietin-stimulating agents, 
commonly used to manage anemia; in carcinogenesis, they are known to activate 
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erythropoietin receptors on the surface of cancer cells. Additionally, erythropoietin-induced 
angiogenesis may promote tumor growth., However, we did not observe temporal trends in 
overall cancer incidence that correlate with the documented rise and fall of erythropoietin-
stimulating agent use and dose. Instead, we observed constant incidence rates over the study 
period, which suggests that erythropoietin-stimulating agent therapy is not related to 
increased cancer incidence.
Our findings are subject to several limitations. First, our results may not be generalizable to 
patients with non–dialysis-dependent chronic kidney disease, patients treated by peritoneal 
dialysis, patients with a non-Medicare primary payer, or patients who died within 9 months 
of dialysis therapy initiation. Second, claims-based cancer definitions commonly are used in 
cancer research, but have not been validated in the ESRD population. We adapted our 
claims-based cancer definition from an algorithm that has high specificity (ie, it minimizes 
false-positives) for several incident cancers in a Medicare population. Third, the possibility 
of overestimating cancer incidence due to misclassification of prevalent cases as incident 
cases cannot be excluded. However, identification of prevalent cases of cancer during the 6-
month baseline period minimized the possibility of misclassification. Fourth, use of claims-
based definitions of cancer made it impossible to determine whether cancers identified as 
incident cases were truly new primary cancers, metastases, or histories of cancer miscoded 
as new primary cancers. Last, information on cancer risk factors was absent from the 
USRDS data.
Strengths of our study include more than a decade of data for the large representative 
population of US patients with ESRD on hemodialysis therapy. The large sample size 
allowed characterization of cancer incidence within subgroups. Additionally, competing-
risks methodology is an innovative approach appropriate for the inherent competing-risks 
problem in the dialysis population due to high annual mortality.
There currently are no standard recommendations for cancer screening in the dialysis 
population (ie, NKF-KDOQI [National Kidney Foundation–Kidney Disease Outcomes 
Quality Initiative] or KDIGO [Kidney Disease: Improving Global Outcomes] guidelines). 
However, our results may help inform clinical decisions regarding screening. Our study 
demonstrates that overall risk of cancer among dialysis patients is higher than that among 
the general population. However, life-expectancy of individuals receiving dialysis is lower 
than that of the general population, and previous cost-effectiveness analyses have suggested 
that general cancer screening would add minimal days of life saved per person.- In practice, 
cancer screening in dialysis patients has been given with an individualized patient-focused 
approach based on the patient's cancer risk factors, expected survival, and transplantation 
status. Our findings of differential cancer incidence among certain subgroups highlight the 
need to potentially reevaluate targeted cancer screening practices. Furthermore, targeted 
screening for certain cancer types should be considered.
In conclusion, we reported a high and constant overall burden of cancer among patients with 
ESRD receiving hemodialysis, with certain subgroups of the population exhibiting a 
particularly elevated cancer risk.
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Adjusted annual incidence rates of cancer diagnoses from 1996 through 2009 for: (A) all 
sites and (B) site-specific cancers. Rates were adjusted for age, sex, race, cause of end-stage 
renal disease, and dialysis vintage in years. Incident cases were defined as the first cancer 
diagnosis of the year among patients without a history of cancer in the last 6 months of the 
previous calendar year. Other cancers were defined as all other site-specific cancers (eg, 
cancers of the esophagus, stomach, and liver). The sum of the site-specific cancer rates 
exceeds the rate for any cancer due to patients diagnosed with multiple cancer sites on the 
same date. Abbreviation: NHL, non-Hodgkin lymphoma.
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Adjusted cancer incidence rates by strata for the top 4 most prevalent cancer sites in years 
1996 to 2009. Incident cases were defined as the first cancer diagnosis of the year among 
patients without a history of cancer in the last 6 months of the previous calendar year. Rates 
were adjusted for age, sex, race, cause of end-stage renal disease (ESRD), and years on 
dialysis therapy. Age adjustment was performed for 4 strata (18-44, 45-64, 65-74, and ≥75 
years), although only 2 categories are presented due to limited case numbers in the 18- to 
44-year age group. The subgroup of interest was omitted from the adjustment for each 
respective subgroup category.
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The cumulative incidence of any cancer among patients with end-stage renal disease 
undergoing hemodialysis, accounting for death as a competing event. The cumulative 
incidence is denoted by a solid line and the 95% confidence intervals are denoted by a dotted 
line. Time at risk for a cancer diagnosis began at 9 months after dialysis therapy initiation.
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The standardized cumulative incidence of any cancer among patients with end-stage renal 
disease (ESRD) undergoing hemodialysis, accounting for the competing risk of death. Time 
at risk for a cancer diagnosis began at 9 months after dialysis therapy initiation. Figures were 
stratified by patient characteristics, including: (A) age at dialysis therapy initiation, (B) sex, 
(C) race, (D) ethnicity, (E) primary cause of ESRD, (F) year of dialysis therapy initiation, 
and (G) history of kidney transplantation evaluation. Cumulative incidence functions were 
standardized to the total study population by combining the cumulative incidence function 
with inverse probability of exposure weights that account for case-mix characteristics (age at 
dialysis therapy initiation, sex, race, ethnicity, primary cause of ESRD, and year of dialysis 
therapy initiation) measured at baseline.
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Table 1
Demographic and Clinical Characteristics of Selected Annual Study Cohorts at Risk for Cancer (1996, 2000, 
2004, and 2009)
Characteristics 1996 2000 2004 2009
No. of patients 88,676 110,897 142,142 164,214
Age at dialysis initiation (y) 61.3 ± 14.8 62.1 ± 14.7 62.7 ± 14.6 62.5 ± 14.5
Age category at dialysis initiation
    18-44 y 13,322 (15.0) 15,235 (13.7) 17,351 (12.2) 19,398 (11.8)
    45-64 y 31,700 (35.8) 39,928 (36.0) 53,421 (37.6) 66,352 (40.4)
    65-74 y 26,869 (30.3) 31,698 (28.6) 37,951 (26.7) 41,136 (25.1)
    ≥75 y 16,785 (18.9) 24,036 (21.7) 33,419 (23.5) 37,328 (22.7)
Male sex 43,934 (49.5) 55,735 (50.3) 73,131 (51.5) 86,406 (52.6)
White race 45,558 (51.4) 56,951 (51.4) 74,470 (52.4) 87,086 (53.0)
Reported cause of ESRD
    Diabetes 31,411 (35.4) 46,862 (42.3) 65,594 (46.2) 79,446 (48.4)
    Hypertension 28,600 (32.3) 33,840 (30.5) 16,464 (30.0) 48,583 (29.6)
    Glomerulonephritis 11,649 (13.1) 14,393 (13.0) 42,591 (11.6) 16,945 (10.3)
    Other 17,016 (19.2) 15,802 (14.2) 17,493 (12.3) 19,240 (11.7)
Dialysis vintage (y) 2.0 [1.0-4.0] 3.0 [1.0-5.0] 3.0 [1.0-5.0] 3.0 [1.0-5.0]
Dialysis vintage category
    <2 y 27,238 (30.7) 33,489 (30.2) 40,212 (28.3) 41,247 (25.1)
    2-5 y 45,480 (51.3) 55,761 (50.3) 73,137 (51.5) 84,289 (51.3)
    >5 y 15,958 (18.0) 21,647 (19.5) 28,793 (20.3) 38,678 (23.6)
History of kidney transplant evaluation
    No 88,676 (100.0) 106,174 (95.7) 132,563 (93.3) 147,731 (90.0)
    Yes 0 (0.0) 4,723 (4.3) 9,579 (6.7) 16,483 (10.0)
Note: Values for categorical variables are given as number (percentage); values for continuous variables are given as mean ± standard deviation or 
median [interquartile range]. Each column represents a separate annual study cohort of prevalent hemodialysis patients that met eligibility criteria 
by January 1 of the respective year. Patients were eligible for multiple cohorts. For brevity, characteristics are presented for only 4 cohorts (ie, 
1996, 2000, 2004, and 2009) and are not presented for 10 cohorts (ie, 1997, 1998, 1999, 2001, 2002, 2003, 2005, 2006, 2007, and 2008).
Abbreviation: ESRD, end-stage renal disease.
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Table 2
Annual Percent Change of Cancer Incidence by Cancer Site, 1996-2009
Cancer Site APC (95% CI)
All sites
a 0.1% (–0.4% to 0.6%)
    Kidney/renal pelvis 2.0% (0.9% to 3.2%)
    Bladder –1.1% (–2.3% to 0.1%)
    Breast, female –0.3% (–1.5% to 0.9%)
    Non-Hodgkin lymphoma –1.1% (–2.4% to 0.2%)
    Lung/bronchus –0.8% (–1.5% to –0.1%)
    Colon/rectum –1.4% (–2.0% to –0.8%)
    Pancreas –2.5% (–3.8% to –1.3%)
    Prostate –0.2% (–1.2% to 0.8%)
    Other sites
        1996–2003 –2.8% (–4.3% to –1.3%)
        2003–2009 1.7% (–0.5% to 3.9%)
Abbreviations: APC, annual percent change; CI, confidence interval.
a
The category for all sites includes all cancer sites diagnosed during the study period, including sites not listed in the table (eg, liver, stomach, and 
esophagus).
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Table 3




Age at dialysis initiation
    18-44 y 3.91% (3.70%-4.11%) 3.81% (3.55%-4.06%)
    45-64 y 7.83% (7.65%-8.00%) 8.07% (7.89%-8.25%)
    ≥65 y 11.17% (11.05%-11.29%) 11.28% (11.15%-11.42%)
Sex
    Male 10.65% (10.53%-10.77%) 10.93% (10.80%-11.05%)
    Female 8.27% (8.14%-8.40%) 8.20% (8.06%-8.33%)
Race
    White 9.75% (9.62%-9.87%) 9.36% (9.23%-9.48%)
    Nonwhite 9.05% (8.91%-9.19%) 9.79% (9.57%-10.00%)
Ethnicity
    Hispanic 7.17% (6.92%-7.41%) 8.54% (7.81%-9.27%)
    Non-Hispanic 9.83% (9.73%-9.93%) 9.65% (9.55%-9.76%)
Reported cause of ESRD
    Diabetes 8.14% (8.02%-8.26%) 8.30% (8.18%-8.42%)
    Hypertension 10.78% (10.60%-10.97%) 10.39% (10.19%-10.59%)
    Glomerulonephritis 10.52% (10.18%-10.87%) 12.01% (11.59%-12.43%)
    Other 11.36% (11.05%-11.67%) 11.54% (11.20%-11.89%)
Calendar period of dialysis initiation
    1995-2002 9.26% (9.15%-9.37%) 9.14% (9.02%-9.25%)
    2003-2010 9.65% (9.51%-9.79%) 9.75% (9.60%-9.89%)
History of kidney transplant evaluation
    No 8.90% (8.79%-9.00%) 8.72% (8.62%-8.82%)
    Yes 10.93% (10.74%-11.12%) 11.67% (11.46%-11.88%)
Note: Values are given as 5-year cumulative incidence (95% confidence interval).
Abbreviation: ESRD, end-stage renal disease.
a
Standardized cumulative incidence estimates account for case-mix characteristics (age at dialysis therapy initiation, sex, race, ethnicity, primary 
cause of ESRD, and year of dialysis therapy initiation) measured at baseline using inverse-probability weights.
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Table 4
The 5-Year Cumulative Incidence of Most Frequent Site-Specific Cancers Among ESRD Patients Undergoing 
Hemodialysis, Accounting for Competing Risk of Death
Cancer Site
a No. of Patients 5-y Cumulative Incidence (95% CI)
Lip, oral cavity, and pharynx
    Tongue 156 0.04% (0.04%-0.05%)
    Mouth 191 0.05% (0.04%-0.06%)
    Pharynx 183 0.05% (0.05%-0.06%)
Digestive system
    Esophagus 369 0.10% (0.09%-0.11%)
    Stomach 590 0.16% (0.15%-0.18%)
    Colon/rectum 4,360 1.18% (1.15%-1.22%)
    Liver 865 0.24% (0.22%-0.26%)
    Gallbladder 202 0.06% (0.05%-0.06%)
    Pancreas 928 0.26% (0.24%-0.28%)
Respiratory system
    Larynx 318 0.09% (0.08%-0.10%)
    Lung/bronchus 4,969 1.36% (1.32%-1.39%)
Bone and cartilage 206 0.06% (0.05%-0.07%)
Skin/connective tissue
b
    Melanoma 872 0.24% (0.22%-0.26%)
    Connective & other soft tissue 285 0.08% (0.07%-0.09%)
Reproductive & genitourinary
    Breast (female)
c 3,688 1.00% (0.97%-1.03%)
    Cervix uteri 345 0.09% (0.08%-0.10%)
    Corpus and uterus 551 0.15% (0.14%-0.16%)
    Ovary 341 0.09% (0.08%-0.10%)
    Prostate 5,396 1.41% (1.37%-1.44%)
    Bladder
c 2,216 0.59% (0.56%-0.61%)
    Kidney/renal pelvis 2,805 0.76% (0.73%-0.79%)
Neurologic
    Brain & other nervous system 560 0.15% (0.14%-0.17%)
Endocrine
    Thyroid 337 0.09% (0.08%-0.10%)
Hematologic
    Non-Hodgkin lymphoma 1,284 0.35% (0.33%-0.37%)
    Myeloma 1,024 0.27% (0.26%-0.29%)
    Leukemia 1,077 0.29% (0.27%-0.31%)
Ill-defined and unspecified 1,941 0.53% (0.51%-0.56%)
Note: Data presented for cancer sites with 150 or more cases during the study period. Table S4 presents results for cancer sites with fewer than 150 
cases.
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Abbreviations: CI, confidence interval; ESRD, end-stage renal disease.
a
Table S1 presents the International Classification of Diseases, Ninth Revision, Clinical Modification codes used in the site-specific cancer 
definitions.
b
Excludes nonmelanoma skin cancer.
c
Malignant and carcinoma in situ.
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Table 5
SIRs of Cancer Among Hemodialysis Patients by Cancer Type, Restricted to Patients of White and Black 
Race, 1996-2009
Cancer Site No. of Observed Cancer Cases SIR (95% CI)
a
All sites
b 35,767 1.42 (1.41-1.43)
    Kidney/renal pelvis 2,712 4.03 (3.88-4.19)
    Bladder 2,165 1.57 (1.51-1.64)
    Breast (female) 3,552 1.42 (1.38-1.47)
    Non-Hodgkin lymphoma 1,251 1.37 (1.30-1.45)
    Lung/bronchus 4,806 1.28 (1.25-1.32)
    Colon/rectum 4,181 1.27 (1.23-1.30)
    Pancreas 891 1.08 (1.01-1.15)
    Prostate 5,248 1.06 (1.03-1.09)
Abbreviations: CI, confidence interval; SEER, Surveillance, Epidemiology, and End Results; SIR, standardized incidence ratio.
a
Indirect standardization was performed by applying background cancer rates from the 2000 US population (SEER 13 registry data by SEER*Stat, 
version 8.1.5) to the age, sex, and race distribution of the study population. Annual age-, sex-, and race-specific rates were averaged over the 14-
year study period (1996-2009). Age was categorized in 5-year groups. Analysis was limited to whites and blacks due to limited availability of rate 
estimates for other race in the SEER general population.
b
The category for all sites includes all cancer sites diagnosed during the study period, including sites not listed in the table (eg, liver, stomach, and 
esophagus).
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